PDF-x0000x0000Contains Nonbinding RecommendationsDraft Guidance on C

Recommended Dec This d raft guidance current thinking on this topic It does not create or confer any rights for or on any person and does not operate to bind the FDA or the public You can use an alt. . It does not create or confer any rights for or on a ny person and does not operate to bind FDA or the public. You can use an alternat ive approach if the approach satisfies the requirements of the applicable statutes and regu lations. If you want to discuss an alternative approach, contact the Of fice of Generic Drugs. Active ingredient: Phentermine Hydrochloride Form/Route: Capsule/Oral Recommended studies: Phentermine Hydrochloride is a DESI ef It does not create or confer any rights for or on any person and does not operate to bind FDA or the public You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations If you want to disc fdagovCosmeticGuidances You may submit written comments regarding th is guidance at any time Submit written comments on the guidance to the Division of Dockets Management H FA305 Food and Drug Administration 5630 Fishers La ne rm 1061 Rockville MD 20 This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and i This draft guidance, once finalized, will represent the Food and Drug Administration ’ s (FDA ’ s) urrent thinking on this topic. It does not create or confer any rights for or on any pers This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and i This d raft guidance , once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic.It does not create or confer any rights for or on any person and does n Guidance for Industry and Food and Drug Administration Staff Document issued on June 21, 2016. This document will be in effect as of September 19, 2016.The draft of this document was issued on May 6, This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does no This draft guidance when finalized will represent the current thinking of the Food and Drug Administration FDA or the Agency on this topic Itdoes not establish any rights for any person and is not bi You may submit electronic or written comments regarding this guidance at any time.Submit electronic comments to http://www.regulations.gov. Submit written comments to the Division of Dockets Manageme This draft guidance, when finalized, will represent the current thinking of the Food and Dr u g Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and U.S. Department of Health and Human ServicesFood and Drug AdministrationCenter for Food Safety and Applied NutritionSeptember ��Contains Nonbinding Recommendations 2 able ofontentsIntrod Labeling of Infant FormulaGuidance for IndustryAdditional copies are available from:Office of Nutrition and Food LabelingFood Labeling and Standards Staff, HFSCenter for Food Safety and Applied Nutrit